Background
Nicobrevin is a proprietary product marketed as an aid to smoking cessation. It contains quinine, menthyl valerate, camphor and eucalyptus oil. 
Objectives
The objective of this review was to assess the effects of Nicobrevin on long‐term smoking cessation 
Search methods
We searched the Cochrane Tobacco Addiction Group trials register. Most recent search was January 2009. 
Selection criteria
Randomized trials comparing Nicobrevin to placebo or an alternative therapeutic control, which reported smoking cessation with at least six months follow up. 
Data collection and analysis
Data were sought on the outcome, method of randomisation, and completeness of follow up. 
Main results
We identified no trials meeting the full inclusion criteria including long‐term follow‐up.
Authors' conclusions
There is no evidence available from long‐term trials that Nicobrevin can aid smoking cessation. 
